Xenon Pharmaceuticals (NASDAQ:XENE) Releases Earnings Results, Beats Estimates By $0.05 EPS

Xenon Pharmaceuticals (NASDAQ:XENE) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.05, FiscalAI reports. During the same period in the previous year, the company earned ($1.07) earnings per share.

Here are the key takeaways from Xenon Pharmaceuticals’ conference call:

• Atera demand significantly exceeded expectations, with booked orders already well above the approximately 40 instruments the company expects to ship in 2026. Management said demand—not customer interest—is the constraint, with manufacturing capacity limiting near-term shipments.
• 10x raised its 2026 revenue outlook to $610 million–$630 million, implying 2%–5% underlying growth excluding settlement revenue. Second-quarter revenue was $151 million, or $149.4 million excluding the $1.6 million Takara settlement, while gross margin improved to 74%.
• Total instrument revenue fell 47% year over year, as customers delayed Xenium and Visium purchases ahead of Atera’s launch. Management expects a modest sequential revenue decline in Q3 from continued spatial transition effects before a significant Q4 increase as Atera shipments ramp.
• Core consumables remained resilient, with total consumables revenue up 7%, spatial consumables up 16%, and single-cell reaction volumes growing at a double-digit rate driven by Flex Apex. Management also characterized AI-driven demand for high-quality single-cell and spatial data as a significant long-term structural tailwind.
• Academic funding conditions remain tenuous; grant sentiment is improving, but funding has not yet translated consistently into purchasing because of allocation delays, oversight, and order-processing bottlenecks. The company’s guidance assumes the current macro environment persists rather than any meaningful academic-market recovery.

Xenon Pharmaceuticals Stock Performance

Shares of XENE traded down $1.19 during mid-day trading on Friday, reaching $63.36. The stock had a trading volume of 720,234 shares, compared to its average volume of 1,308,280. The firm has a market cap of $6.13 billion, a price-to-earnings ratio of -13.48 and a beta of 0.62. Xenon Pharmaceuticals has a 12 month low of $32.78 and a 12 month high of $72.66. The business has a fifty day moving average of $60.06 and a 200 day moving average of $54.14.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the sale, the director directly owned 1,455 shares in the company, valued at $77,318.70. This trade represents a 44.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the transaction, the director owned 24,896 shares in the company, valued at approximately $1,322,973.44. This trade represents a 5.04% decrease in their position. The SEC filing for this sale provides additional information. 2.91% of the stock is owned by company insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Danske Bank A S purchased a new stake in shares of Xenon Pharmaceuticals during the third quarter worth about $32,000. Kestra Advisory Services LLC purchased a new position in Xenon Pharmaceuticals in the 4th quarter worth approximately $33,000. Osaic Holdings Inc. boosted its stake in Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,034 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Xenon Pharmaceuticals in the 4th quarter worth approximately $43,000. Finally, State of Wyoming grew its holdings in Xenon Pharmaceuticals by 30.4% during the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 350 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on XENE. Wall Street Zen raised Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Needham & Company LLC cut their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. JPMorgan Chase & Co. upped their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research report on Wednesday, May 27th. Royal Bank Of Canada dropped their price objective on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a report on Friday. Finally, Wells Fargo & Company restated an “overweight” rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $77.13.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.